User Reviews for Tilmanocept
Also known as: Lymphoseek
Reviews may be moderated or edited before publication to correct grammar and spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest in the medication will not be published. As reviews and ratings are subjective and self-reported, this information should not be used as the basis for any statistical analysis or scientific studies.
Lymphoseek (tilmanocept) for Diagnosis and Investigation: “Conduced first exploratory use in June, 2013 indication cutaneous melanoma, Breslow/3mm. Tilmanocept was well received by the patient with no local. Clearance delay provision <20 min. SLN discovery total <4 min/2 SLN/Path.”
This information is NOT intended to endorse any particular medication. While these reviews might be helpful, they are not a substitute for the expertise, knowledge and judgement of healthcare practitioners.